Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?

Antonios N. Gargalionis; Kostas A. Papavassiliou; Athanasios G. Papavassiliou

doi:10.3390/ijms25126309

International Journal of Molecular Sciences (Jun 2024)

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?

Antonios N. Gargalionis,
Kostas A. Papavassiliou,
Athanasios G. Papavassiliou

Affiliations

Antonios N. Gargalionis: Laboratory of Clinical Biochemistry, ‘Attikon’ University General Hospital, Medical School, National and Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece
Kostas A. Papavassiliou: First University Department of Respiratory Medicine, ‘Sotiria’ Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Athanasios G. Papavassiliou: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

DOI: https://doi.org/10.3390/ijms25126309
Journal volume & issue: Vol. 25, no. 12
p. 6309

Abstract

Read online

Lung cancer has been established as the second most common cancer worldwide (most common cancer in men and second most common cancer in women) and as the leading cause of cancer morbidity among neoplasms [...]

n/a

Published in International Journal of Molecular Sciences

ISSN: 1661-6596 (Print); 1422-0067 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General); Science: Chemistry
Website: http://www.mdpi.com/journal/ijms

About the journal

Abstract

Keywords